Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha Sells 55,000 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the firm’s stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $16.53, for a total value of $909,150.00. Following the transaction, the chief executive officer now owns 721,924 shares of the company’s stock, valued at $11,933,403.72. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Saurabh Saha also recently made the following trade(s):

• On Tuesday, September 10th, Saurabh Saha sold 175,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.52, for a total value of $2,891,000.00.
• On Thursday, August 22nd, Saurabh Saha sold 506 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.23, for a total value of $6,188.38.
• On Tuesday, August 20th, Saurabh Saha sold 4,169 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $12.32, for a total value of $51,362.08.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $16.58 on Monday. The firm has a market capitalization of $1.67 billion, a PE ratio of -11.68 and a beta of 1.44. Centessa Pharmaceuticals plc has a fifty-two week low of $5.15 and a fifty-two week high of $17.59. The stock’s 50-day simple moving average is $12.41 and its 200-day simple moving average is $10.67. The company has a debt-to-equity ratio of 0.27, a quick ratio of 13.29 and a current ratio of 13.29.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). As a group, equities research analysts forecast that Centessa Pharmaceuticals plc will post -1.61 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on CNTA shares. Guggenheim lifted their price objective on Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Oppenheimer reiterated an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, August 14th. B. Riley started coverage on Centessa Pharmaceuticals in a research note on Thursday. They issued a “buy” rating and a $33.00 price objective for the company. Jefferies Financial Group lifted their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Finally, Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $11.00 to $26.00 in a research note on Thursday. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $25.17.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Quarry LP increased its position in Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after buying an additional 3,108 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Centessa Pharmaceuticals by 69.2% during the first quarter. China Universal Asset Management Co. Ltd. now owns 10,817 shares of the company’s stock worth $122,000 after buying an additional 4,423 shares during the period. EntryPoint Capital LLC acquired a new position in Centessa Pharmaceuticals during the first quarter worth approximately $109,000. Sandia Investment Management LP acquired a new position in Centessa Pharmaceuticals during the second quarter worth approximately $90,000. Finally, Fred Alger Management LLC acquired a new position in Centessa Pharmaceuticals during the second quarter worth approximately $99,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.